Vaccine Therapy in Treating Patients With Metastatic, Progressive Prostate Cancer
Completed · Phase 1
Conditions studied: Prostate Cancer
In brief
RATIONALE: Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. PURPOSE: This phase I trial is studying the side effects of a peptide vaccine in treating patients with metastatic prostate cancer.
Key facts
- Study ID
- NCT00616291
- Run by
- Baylor College of Medicine
- People needed
- 14
- Starts
- 2006-04-01
- Expected to finish
- 2011-07-01
- Last updated by the study team
- 2012-11-06
Who can join
Age: 18 and older. Sex: male. Healthy volunteers: not accepted.
Where it is running
- Dan L. Duncan Cancer Center at Baylor College of Medicine — Houston, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.